Epidemiology of invasive fungal diseases in a reference center of pediatric oncology in Brazil.

2018 ◽  
Author(s):  
FABIANNE Carlesse
Keyword(s):  
Pediatric Oncology ◽  
Fungal Diseases ◽  
Reference Center ◽  
Invasive Fungal Diseases

scholarly journals Prospective Evaluation of Serum β-Glucan Testing in Patients With Probable or Proven Fungal Diseases

2016 ◽  
Vol 3 (3) ◽  
Author(s):  
Cécile Angebault ◽  
Fanny Lanternier ◽  
Frédéric Dalle ◽  
Cécile Schrimpf ◽  
Anne-Laure Roupie ◽  
...  
Keyword(s):  
Clinical Utility ◽  
Clinical Suspicion ◽  
Fungal Diseases ◽  
Prospective Evaluation ◽  
Invasive Fungal Diseases ◽  
Undetectable Serum ◽  
Antifungal Use ◽  
Kinetics Of ◽  
Rule Out

Abstract Background.  Early diagnosis and treatment are crucial in invasive fungal diseases (IFD). Serum (1-3)-β-d-glucan (BG) is believed to be an early IFD marker, but its diagnostic performance has been ambiguous, with insufficient data regarding sensitivity at the time of IFD diagnosis (TOD) and according to outcome. Whether its clinical utility is equivalent for all types of IFD remains unknown. Methods.  We included 143 patients with proven or probable IFD (49 invasive candidiasis, 45 invasive aspergillosis [IA], and 49 rare IFD) and analyzed serum BG (Fungitell) at TOD and during treatment. Results.  (1-3)-β-d-glucan was undetectable at TOD in 36% and 48% of patients with candidemia and IA, respectively; there was no correlation between negative BG results at TOD and patients' characteristics, localization of infection, or prior antifungal use. Nevertheless, patients with candidemia due to Candida albicans were more likely to test positive for BG at TOD (odds ratio = 25.4, P = .01) than patients infected with other Candida species. In 70% of the patients with a follow-up, BG negativation occurred in >1 month for candidemia and >3 months for IA. A slower BG decrease in patients with candidemia was associated with deep-seated localizations (P = .04). Thirty-nine percent of patients with rare IFD had undetectable BG at TOD; nonetheless, all patients with chronic subcutaneous IFD tested positive at TOD. Conclusions.  Undetectable serum BG does not rule out an early IFD, when the clinical suspicion is high. After IFD diagnostic, kinetics of serum BG are difficult to relate to clinical outcome.

scholarly journals Use of Multimodality Imaging in Diagnosing Invasive Fungal Diseases of the Heart

2017 ◽  
Vol 10 (6) ◽  
Author(s):  
Ersilia M. DeFilippis ◽  
Sarah Cuddy ◽  
Carolyn Glass ◽  
Sarv Priya ◽  
Ayaz Aghayev ◽  
...  
Keyword(s):  
Multimodality Imaging ◽  
Fungal Diseases ◽  
Invasive Fungal Diseases

scholarly journals Editorial: Host and Pathogen Determinants of Allergic and Invasive Fungal Diseases

2020 ◽  
Vol 11 ◽  
Author(s):  
Joshua J. Obar ◽  
Agostinho Carvalho ◽  
Joana Vitte ◽  
Stéphane Ranque
Keyword(s):  
Fungal Diseases ◽  
Invasive Fungal Diseases

scholarly journals Clinicians’ challenges in managing patients with invasive fungal diseases in seven Asian countries: An Asia Fungal Working Group (AFWG) Survey

2020 ◽  
Vol 95 ◽  
pp. 471-480 ◽  
Author(s):  
Ban Hock Tan ◽  
Arunaloke Chakrabarti ◽  
Atul Patel ◽  
Mitzi Marie M. Chua ◽  
Pei-Lun Sun ◽  
...  
Keyword(s):  
Working Group ◽  
Fungal Diseases ◽  
Asian Countries ◽  
Invasive Fungal Diseases
Sign in / Sign up

Export Citation Format

Share Document